Debiopharm turns to China for latest oncology licensing deal
This article was originally published in Scrip
Executive Summary
In another sign of China's gradual emergence as a source of innovative research in the pharma sector, Debiopharm Group has found a novel oncology candidate from a small Chinese firm sufficiently attractive to acquire global rights.